Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
Status:
Recruiting
Trial end date:
2036-05-01
Target enrollment:
Participant gender:
Summary
This is a single-center, phase 1b study evaluating the safety and feasibility of a
neoadjuvant treatment with tucatinib, trastuzumab and pertuzumab in stage II-IIIA
HER2-positive breast cancer.